南星骨痛凝胶贴膏对兔膝骨关节炎关节形态及血清IL-1、TNF-α、MMP-13、TIMP-1表达的影响

目的观察南星骨痛凝胶贴膏对兔膝骨关节炎关节形态及血清IL-1、TNF-α、MMP-13、TIMP-1表达的影响,探讨南星骨痛凝胶贴膏治疗兔膝骨关节炎可能的作用机制。方法 18只健康6月龄新西兰兔随机分成3组:空白组(A组)、模型组(B组)、骨痛膏治疗组(C组). BC组用3%木瓜蛋白酶关节腔内注射造模后C组给予南星骨痛凝胶贴膏外敷,给药4周后,用Aloka Latheta LCT-200观察兔膝骨关节影像学改变、用ELISA法检测血清IL-1、TNF-α、MMP-13、TIMP-1含量。结果 C组兔膝关节病变程度较B组轻,C组兔血清中IL-1、TNF-α、MMP-13含量较B组降低(P<0. 05),TIMP-1含量较B组升高(P <0. 05)。结论南星骨痛凝胶贴膏能减轻兔膝关节骨关节炎病变程度,对关节软骨有保护作用,其作用机制可能与抑制炎症因子IL-1、TNF-α及MMP-13表达,增加TIMP-1表达有关。     

基于VAS评价右美托咪定在宫颈癌根治术后镇痛及术后快速康复中的临床效果

目的:研究右美托咪定在宫颈癌根治术后镇痛及术后快速康复中的临床应用效果。方法:将2015年7月至2018年7月在本院行宫颈癌根治术的86例患者随机分为对照组和观察组各43例。对照组术后镇痛采用舒芬太尼和格拉司琼，观察组术后镇痛加用右美托咪定。采用视觉模拟评分法（VAS）评价患者术后1 h、6 h、12 h、24 h、48 h疼痛情况，采用Ramesay评分法评价患者不同时间点镇静状况，记录并比较两组患者不同时间点收缩压、舒张压、心率及呼吸频率变化，比较两组患者不良反应发生情况。结果:观察组患者术后6 h、12 h、24 h、48 h VAS评分均明显低于对照组（P＜0.05），Ramesay评分均明显高于对照组（P＜0.05）；观察组和对照组患者术后不同时间点呼吸频率比较，差异无统计学意义，但术后6 h、12 h、24 h观察组患者收缩压、心率均明显低于对照组（P＜0.05），术后1 h、6 h观察组患者舒张压明显低于对照组（P＜0.05）；观察组患者恶心呕吐、高血压发生率较对照组明显减低。结论:右美托咪定用于宫颈癌根治术后镇痛，可以提高镇痛镇静效果，稳定患者血流动力学，有助于术后快速康复。     

Prostate imaging: Contribution of PET PSMA and MRI

Prostate cancer is the most common malignant tumour and represents the third cause of cancer-mortality in men. The management of prostate cancer has dramatically changed over the last decades, mainly due to improvement of diagnostic modalities and development of new therapeutic strategies. Imaging plays a key role in all the steps of prostate cancer management. In recent years, magnetic resonance imaging (MRI) and positron-emission tomography (PET) – computed tomography (CT) have emerged as two major tools for the detection of prostate cancer, tumour staging and treatment choice. Both MRI and PET-CT – using choline or prostate-specific membrane antigen (PSMA) as radiotracer – have become mandatory. This article presents the contribution of the latest advances in these two imaging techniques of prostate cancer and their future developments.     

Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan

To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012‐2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2‐3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). The Roche Linear Array was used for HPV genotyping. The HPV type‐specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type‐specific RCs between CIN1 and CIN2‐3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type‐specific risks for progression to CIN2+. Human papillomavirus DNA was detected in 85.5% of CIN1, 95.7% of CIN2‐3/AIS, and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2‐3/AIS, and 23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01‐4.98), followed by HPV31 (2.51, 1.54‐5.24), HPV18 (2.43, 1.59‐4.32), HPV35 (1.56, 0.43‐8.36), HPV33 (1.01, 0.49‐3.31), HPV52 (0.99, 0.76‐1.33), and HPV58 (0.97, 0.75‐1.32). The relative risk of disease progression was 1.87 (95% CI, 1.71‐2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14‐0.22) for HPV39/51/56/59/66/68. Human papillomavirus 16/18/31/33/45/52/58/6/11 included in a 9‐valent vaccine contributed to 89.7% (95% CI, 88.7‐90.7) of CIN2‐3/AIS and 93.8% (95% CI, 92.4‐95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9‐valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women.     

肌骨超声在腰痛诊断中的应用

腰痛已成为世界范围内主要的公共健康问题,常规的腰痛影像学检查会反复地对患者造成辐射伤害,并且存在一定的漏诊、误诊的可能性,延误治疗时机。肌骨超声是一种非侵入性的成像方法,具有安全、无创的特点,并且价格低廉,已经作为常用的腰痛辅助筛查手段。通过对腰痛的常规影像学检查手段进行分析比较,全面阐述肌骨超声在腰痛的诊断及康复过程中的价值,为更好地促进腰痛的诊断和康复提供理论基础。     

HPV治疗性疫苗的研究进展

宫颈癌是影响全球女性健康的公共卫生问题。持续的高危型HPV感染是宫颈癌的主要致病因素。目前，HPV预防性疫苗已经在全球范围内逐渐广泛开展，但其对已感染HPV的女性没有治疗作用。迄今，多种治疗性疫苗已用于临床前模型和临床试验，包括肽和蛋白质疫苗、活载体疫苗、DNA疫苗等，并已经显示出良好的安全性和耐受性，为宫颈癌的防治工作带来了希望和动力。但其仍存在免疫原性低、需要寻找更多新的靶抗原基因等不足，仍需进一步研究。     

2015年重庆市肿瘤登记地区宫颈癌疾病负担分析

目的:了解2015年重庆市宫颈癌发病率、死亡率、伤残调整寿命年。方法:收集整理2015年重庆市11个肿瘤登记点报告的宫颈癌发病死亡病例（ICD-10编码为C53）。统计分析宫颈癌发病率、死亡率、标化发病率、标化死亡率、发病和死亡截缩率、发病或死亡累积危险度、早死所致的寿命损失年、残疾所致寿命损失年、伤残调整寿命年等指标。城市与农村宫颈癌发病率与死亡率的比较采用χ2检验。 结果:2015年重庆市肿瘤登记地区共报告宫颈癌新发病例916例，宫颈癌粗发病率为18.29/105，标化发病率为14.26/105，标化发病率农村（15.60/105）高于城市（12.32/105），差异有统计学意义（P<0.001）。2015年共报告宫颈癌死亡病例283例，粗死亡率为5.65/105，标化死亡率为3.98/105。2015年重庆市宫颈癌截缩发病率为32.60/105，截缩死亡率为8.32/105，发病率与死亡率累积危险度分别为1.41%与0.49%。宫颈癌导致的DALYs、YLDs 和YLLs分别是6.76千人年、5.00千人年与1.76千人年。结论:重庆市宫颈癌发病率与死亡率高于全国平均水平，疾病负担重，疾病负担农村高于城市。     

针刀松解激痛点治疗颈源性头痛39例影响

目的分析针刀松解激痛点治疗方法用于颈源性头痛患者的效果。方法对医院接受针刀松解激痛点治疗的39例颈源性头痛患者纳入试验组,选于2017年2月—2018年9月,抽取同期接受针刺治疗的39例颈源性头痛患者纳入对照组,评比两组治疗有效总计率、治疗前和治疗3个疗程后头痛程度评分值、头痛维持时间、头痛发生频率。结果试验组治疗有效总计率明显高于对照组统计值(P<0.05)。试验组治疗3个疗程后头痛程度评分值、头痛维持时间、头痛发生频率显著低于治疗前及对照组统计值(P<0.01)。结论对颈源性头痛患者实行针刀松解激痛点治疗的效果较优。     

Research progress on magnetic resonance imaging-guided proton therapy for tumors

With the application of magnetic resonance imaging (MRI)-guided photon therapy, the concept of combining real-time MRI guidance with proton therapy, namely, MRI-guided proton therapy (MRPT), has attracted widespread attention. It is expected that MRPT canmitigate the uncertaintiesduring the treatment of proton therapy to make full use of the physical advantages of protons. However, multiple electromagnetic interactions between proton therapy and MRI-guided systems may lead to mutual interference between the two systems. This article review the research progress on the MRPT system, aiming to provide certain reference for the design of MRPT system.